At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren (Memorial Sloane Kettering Cancer Center, New York, NY) debates the requirement of intense treatment in relapsed multiple myeloma.
Dr Landgren refers to results of the phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed multiple myeloma. Although patient outcomes have improved with these new and milder treatments, there is a need to understand patient subgroups that do not response to these treatments.